NUTX

Rating neutralAI Memo

Nutex Health

As of 2026-07-11/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-11 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q1 2026 results kept the earnings base intact, but same-hospital growth stayed muted • 2026-04-30

Expected move: +29%

Biggest risk

The bear case is that same-hospital revenue growth of just 0.2% and same-hospital visit growth of 0.6% suggest limited organic acceleration, while a meaningful share of profitability still depends on high-acuity claims and favorable IDR outcomes that carry regulatory and payor-behavior risk [#8-K-2026-04-30] [#10-K-2026-03-05].

Invalidation

Break below $140 or thesis failure.

What would change my mind?

The bull case is that Q1 2026 showed real earnings and cash generation support, with revenue up to $216.5 million, net income at $46.8 million, operating cash flow at $75.5 million, and cash at $207.3 million, while planned hospital openings provide an additional growth leg if executed [#8-K-2026-04-30].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-11

Base target

$210

p=45%

Bull target

$255

p=30%

Bear target

$140

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Near-term cash deployment and share retirement can help per-share optics if collections remain strong
Three planned hospital openings and selective self-development are the main 2026 growth proof points
The bull case is that Q1 2026 showed real earnings and cash generation support, with revenue up to $216.5 million, net income at $46.8 million, operating cash flow at $75.5 million, and cash at $207.3 million, while planned hospital openings provide an additional growth leg if executed [#8-K-2026-04-30].

BearKey bullets

Arbitration is profitable today, but Nutex said arbitration costs approximate 35% of arbitration-related revenue, so margin durability depends on continued favorable awards and efficient collections [#8-K-2026-04-30].
Execution risk on three planned hospital openings and selective self-development is material; delays or weaker-than-expected ramp could keep the stock in monitoring mode [#10-K-2026-03-05] [#8-K-2026-04-30].
Same-hospital growth was soft in Q1 2026, with same-hospital revenue up only 0.2% and same-hospital visits up 0.6%, leaving limited room for execution misses [#8-K-2026-04-30].

WatchKey bullets

Q1 2026 results kept the earnings base intact, but same-hospital growth stayed muted

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $210 (p=45%)

Bull/Bear spread: +56% / -14%

Vs latest close: Bull +56% · Base +29% · Bear -14%

Scenario probabilities

Bull Target: $255 (p=30%)Base Target: $210 (p=45%)Bear Target: $140 (p=25%)

Commentary

Recent attention in the packet is still mostly earnings-summary and valuation-syndication coverage rather than a broad post-print analyst revision cycle. Primary evidence quality is strong because the thesis is anchored by SEC-backed Q1 2026 disclosures and the 2025 Form 10-K, but forward visibility remains only moderate because same-hospital growth was muted and the story is still concentrated in IDR economics, regulatory sensitivity, and execution on planned openings. Social-context coverage was not provided, so this remains a monitoring-style setup rather than a high-conviction momentum call.

As of 2026-07-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Near-term cash deployment and share retirement can help per-share optics if collections remain strong
Three planned hospital openings and selective self-development are the main 2026 growth proof points

Scenarios

Bull Target (Scenario probability)

$255 / p=30% prob

Base Target (Scenario probability)

$210 / p=45% prob

Bear Target (Scenario probability)

$140 / p=25% prob

Price $163 as of 2026-07-17

Nearest Scenario: Bear (∆ 14%)

Targets vs latest close: Bull +56% · Base +29% · Bear -14%

Sentiment & Exposure

News Sentiment (30d)

0.18

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-04-30
Q1 2026 results kept the earnings base intact, but same-hospital growth stayed muted
The April 30, 2026 earnings release reported Q1 2026 revenue of $216.5 million, net income attributable to Nutex of $46.8 million, diluted EPS of $6.52, operating cash flow of $75.5 million, same-hospital revenue growth of 0.2%, same-hospital visits up 0.6%, and an over 85% win rate on decided IDR determinations. That supports the current earnings base, but it does not yet show broad same-facility acceleration and keeps the thesis tied to reimbursement capture and collections durability [#8-K-2026-04-30] [#SEC-8K-2026-04-30].
Prob 85.00% • Move 6.00% • Priced-in 80.00%

Short-term Catalysts

Next few weeks

Near-term cash deployment and share retirement can help per-share optics if collections remain strong
2026-09-30
The Q1 2026 Form 10-Q showed 118,867 shares repurchased under the August 2025 program, 21,061 shares repurchased under the March 2026 program, and 60,516 shares retired under settlement agreements, for 200,444 total shares repurchased and retired in the quarter. That gives Nutex some near-term per-share support, but only if the elevated operating cash generation and reimbursement collections seen in Q1 prove durable [#10-Q-2026-04-30].
Prob 60% • Move 5% • Priced-in 55%

Long-term Catalysts

Months to a year

Three planned hospital openings and selective self-development are the main 2026 growth proof points
2026-12-31
Management said it expects to open three new hospital facilities by the end of 2026, with those facilities under construction or in advanced planning, and the Q1 2026 earnings release added that the board approved selective self-development of new facilities through the real estate division. If those openings convert into volume and mix, the market can give more credit to the growth pipeline; if they slip, the story remains overly dependent on IDR economics [#10-K-2026-03-05] [#8-K-2026-04-30].
Prob 55% • Move 12% • Priced-in 45%

Risks

Arbitration is profitable today, but Nutex said arbitration costs approximate 35% of arbitration-related revenue, so margin durability depends on continued favorable awards and efficient collections [#8-K-2026-04-30].
Execution risk on three planned hospital openings and selective self-development is material; delays or weaker-than-expected ramp could keep the stock in monitoring mode [#10-K-2026-03-05] [#8-K-2026-04-30].
Same-hospital growth was soft in Q1 2026, with same-hospital revenue up only 0.2% and same-hospital visits up 0.6%, leaving limited room for execution misses [#8-K-2026-04-30].
The operating story remains highly exposed to the No Surprises Act and the IDR process; regulatory or payor-behavior changes could pressure reimbursement and collections [#10-K-2026-03-05].

Peers

Symbol	Summary
AMN	AMN Healthcare is the closest services-oriented public comp in the packet, but it is still a loose comparable because staffing and workforce solutions do not map cleanly to Nutex’s micro-hospital, physician-network, and claims-collection model.
AHG	Akso Health Group is closer on market cap than on operations, making it a weak comp for Nutex’s U.S. reimbursement, facility-development, and IDR-sensitive earnings profile.
IRMD	IRadimed is a similarly sized healthcare name, but it is fundamentally a device company rather than a healthcare-operations platform, so it is more a valuation-risk comp than a direct operating peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-11

AI Stock Memo: NUTX - Nutex Health - RankAlpha